HL 1225

Drug Profile

HL 1225

Alternative Names: HL1225

Latest Information Update: 03 Oct 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Handok Pharmaceuticals
  • Developer Handok Inc
  • Class Antihyperglycaemics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Diabetes mellitus

Most Recent Events

  • 03 Oct 2013 Discontinued - Phase-II for Diabetes mellitus in South Korea (unspecified route)
  • 01 Jul 2013 Handok Pharmaceuticals is now called Handok Inc.
  • 22 Jun 2011 HL 1225 is available for partnering as of 22 Jun 2011. http://www.handok.co.kr
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top